Search hospitals > New York > Albany
Neurological Associates of Albany, PC
Claim this profileAlbany, New York 12208
Global Leader in Alzheimer's Disease
Conducts research for Dementia
Conducts research for Mild Cognitive Impairment
Conducts research for Cognitive Impairment
Conducts research for Alzheimer's Dementia
41 reported clinical trials
1 medical researcher
Summary
Neurological Associates of Albany, PC is a medical facility located in Albany, New York. This center is recognized for care of Alzheimer's Disease, Dementia, Mild Cognitive Impairment, Cognitive Impairment, Alzheimer's Dementia and other specialties. Neurological Associates of Albany, PC is involved with conducting 41 clinical trials across 21 conditions. There are 1 research doctors associated with this hospital, such as Richard Holub, MD.Area of expertise
1Alzheimer's Disease
Global LeaderApoE positive
ApoE negative
APOE4 positive
2Dementia
Top PIs
Clinical Trials running at Neurological Associates of Albany, PC
Alzheimer's Disease
Mild Cognitive Impairment
Alzheimer's Dementia
Cognitive Impairment
Dementia
Alzheimer's
Cognitive Decline
Late Onset Disorders
Aducanumab
for Alzheimer's Disease
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
Recruiting1 award Phase 31 criteria
JNJ-64042056
for Alzheimer's Disease
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.
Recruiting0 awards Phase 21 criteria
BIIB080
for Alzheimer's Disease
In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on what dose of BIIB080 slows worsening of AD the most. To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB. Clinicians use the CDR-SB to measure several categories of dementia symptoms. The results for each category are added together for a total score. Lower scores are better. Researchers will also learn more about the safety of BIIB080. A description of how the study will be done is given below. Participants will receive either a low dose or high dose of BIIB080 or a placebo as an injection into the fluid around the spinal cord. A placebo looks like the study drug but contains no real medicine. The fluid around the spinal cord is called the cerebrospinal fluid. Participants will be in the study for 105 weeks, or a little over 2 years. This includes the screening and follow-up periods. Participants will be given BIIB080 or placebo once every 12 weeks for a total of 72 weeks. Participants can continue to take certain medications for AD. Participants must be on the same dose of medication for at least 8 weeks before the screening period. After the screening period, most participants will visit the clinic every 6 weeks.
Recruiting0 awards Phase 24 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Neurological Associates of Albany, PC?
Neurological Associates of Albany, PC is a medical facility located in Albany, New York. This center is recognized for care of Alzheimer's Disease, Dementia, Mild Cognitive Impairment, Cognitive Impairment, Alzheimer's Dementia and other specialties. Neurological Associates of Albany, PC is involved with conducting 41 clinical trials across 21 conditions. There are 1 research doctors associated with this hospital, such as Richard Holub, MD.